MSF teams have completed a preventive cholera vaccination campaign in and around the refugee camps in Maban County, South Sudan. Hoping to prevent the spread of the potentially fatal disease, staff vaccinated 105,000 refugees in four camps and 27,500 other residents of the area.
MSF launched the vaccination campaign with the cooperation of South Sudan’s Ministry of Health as part of a cholera preparedness and prevention plan. While teams have already set up and pre-stocked cholera treatment facilities in the camps, the remoteness of the area and supply challenges mean that a cholera outbreak could be disastrous. That's what makes the added prevention provided by a vaccination campaign so crucial.
“The key for preventing cholera is to ensure sufficient access to clean drinking water, and to have appropriate sanitation and hygiene facilities,” says Paul Critchley, MSF emergency coordinator in Maban County. “We are currently tackling an escalating hepatitis E outbreak in the camps, so we know that sanitation conditions here are not yet adequate. Hepatitis E is spread in similar ways to cholera, and this reinforces the need to do all we can to prevent cholera breaking out too.”
Around 110,000 refugees who have fled the ongoing conflict in neighboring Sudan’s Blue Nile State have gathered in four refugee camps. Living conditions in the camps are extremely harsh, and refugees are entirely dependent on humanitarian organizations. With no easy access routes, it was a challenge for MSF to bring in 19,200-liter refrigerators, the generators to keep them running, and the 290,000 vials of vaccine. Despite these logistical challenges, this innovative approach to cholera prevention is justified in a situation where a population is exceptionally vulnerable and where the consequences of an outbreak would be particularly devastating.
The vaccine comes in the form of oral drops and was given to each person twice, with a gap of two to three weeks between doses. By deploying a substantial health promotion effort in advance, the teams were able to reach more than 132,000 people with both doses of the vaccine. The MSF teams were supported by staff from GOAL, IOM, Medair, Relief International, Solidarités, and South Sudan’s Ministry of Health.
“The logistical difficulty of this vaccination campaign highlights the need for further development of more field-adapted vaccines,” says Dr. Jennifer Cohn, medical director for MSF’s Access Campaign. “While it is helpful that the vaccine is an oral administration, which assists in the ease of its administration, it comes in one dose per vial and must be kept in a cold chain, which means the sheer bulk and logistics of supplying some 290,000 doses makes using this vaccine challenging in locations where it may have the greatest benefit. The vaccine also must be given in two doses, at least 14 days apart. Ensuring both doses are given is difficult in situations of disaster or with mobile populations. A formulation that can be packaged in multi-dose vials and can be used without strict cold chain would greatly improve the logistical challenges of such important vaccination activities. Further, the price is an issue. If the cost could be reduced, that would further increase the scope for widespread use of the vaccine.”
Although the vaccine provides significant immunity to cholera, it does not by itself guarantee that there will be no outbreak. While the high vaccine coverage achieved will help to substantially limit the spread of a potential outbreak, all efforts possible must still be made by the organizations working on water and sanitation in the camps to control the hepatitis E epidemic and to limit the risk of a cholera outbreak.
MSF has worked in the refugee camps in Maban since November 2011 and is currently running three field hospitals and seven health posts, providing around 5,500 consultations per week across the four refugee camps.
Related News & Publications
Be part of MSF
Our supporters, donors and fundraisers are a vital part of the MSF movement.
Find out how you can support MSF's lifesaving work.